Introduction
Hairy cell leukemia (HCL) is a rare lymphoproliferative disorder with distinct clinicomorphological features and specific cytochemical 1 and immunohistochemical 2 characteristics. An important step in the elucidation of the pathogenesis of hairy cell leukemia was the description of the BRAF c.1799T>A p.Val600Glu V600E mutation in 48 patients with HCL. 3 In this cohort, the BRAF V600E mutation was detected by direct Sanger sequencing (SS) of PCR products from Ficoll density gradient enriched, magnetic-activated cell sorted peripheral blood from patients with known HCL. Whilst this enrichment technique results in high purity leukemia samples (>90%), in the context of a diagnostic molecular laboratory, a more cost-effective, rapid and less labour intensive method that is capable of high throughput is desirable. High resolution melting (HRM) analysis is a DNA mutation screening technique which is fast, relatively simple and has previously been shown to be a sensitive and reliable way of detecting the BRAF V600E mutation in tumour samples from patients with melanoma 4 ,colorectal carcinoma 5 and, more recently, HCL. 6 Our aim was to determine the feasibility of using HRM analysis and subsequent SS to detect the BRAF V600E in DNA extracted from unenriched bone marrow aspirate and peripheral blood samples from patients with HCL. We also aimed to confirm and extend the initial observation of Tiacci et al 3 using HRM and SS to detect the BRAF V600E mutation in patients with HCL (including immunophenotypic variants) as well as screening morphological mimics of HCL (HCL-variant (HCL-v) and marginal zone lymphoma (MZL)) and other hematological malignancies. 
Results and Discussion
Fifty-nine samples (58 bone marrow aspirates and 1 peripheral blood) from 51 patients with HCL and 34 samples (33 bone marrow aspirates and 1 peripheral blood) from 34 patients with other hematological malignancies were identified. In the HCL group, 32 samples were from specimens taken at initial diagnosis and 27 were taken after treatment, either at time of clinical relapse or as part of a post-treatment assessment. The results of HRM analysis and subsequent SS on HRM positive samples is summarised in Table 1 .
All samples from HCL patients with an estimated mutant allele percentage of greater than 6.75% had mutations evident by HRM analysis (33 samples from 32 patients).
9 out of 26 samples from HCL patients with an estimated mutant allele percentage of less than or equal to 6.75% had mutations evident by HRM analysis. The sensitivity of HRM in both the published literature [5] [6] 8 and in our own experience is a mutant allele percentage of approximately 5-10% depending on the precise mutation.
Therefore all samples with an estimated mutant allele percentage that was above the accepted limits of detection (LOD) of HRM analysis had mutations evident.
Of the 42 samples from patients with HCL with mutations detected by HRM, the BRAF V600E was detected by confirmatory sequencing in 38. Of the remaining 4 samples, 3 had equivocal sequencing results (estimated mutant allele percentages of 8.5%, 7.5% and 5.25%) and 1 sample had a wild-type sequence (estimated mutant allele percentage of 7%). In our experience, the sensitivity of SS in this context is a mutant allele percentage of 10-20%. Given the typical mutation curves evident on HRM analysis in these patients, it is likely that these samples contained the BRAF V600E mutations but were below the sensitivity of SS. One patient with SMZL had a mutation detected by HRM analysis with a BRAF c.1801A>G p.Lys601Glu (K601E) mutation identified on subsequent sequencing.
The pathological features of the case are shown in Figure 1 . The patient, a 75 year old male, presented with a marked lymphocytosis (130x10 9 /L), massive splenomegaly and constitutional symptoms. The disease course of this patient was aggressive and was refractory to both single agent chlorambucil and then subsequently to cyclophosphamide plus etoposide. There was a brief hematological response to single agent fludarabine but the patient died of progressive lymphoma 10 months after initial diagnosis. The BRAF K601E mutation was detected in aspirate samples taken both at diagnosis and later in the course of disease.
The pathological features of this case strongly favour a diagnosis of SMZL rather than HCL according to current classification standards. 7 The disease course was more aggressive than is typically observed for SMZL, however, immunohistochemistry showed strong nuclear staining for p53 which suggests a TP53 mutated status that has been associated with a poorer prognosis in SMZL. 9 Importantly, there was no morphological evidence on bone marrow biopsy of large cell transformation. The precise molecular pathogenesis of SMZL remains unclear. The identification of the first case of SMZL harbouring a BRAF K601E mutation has potential implications for the molecular pathogenesis of this condition. The BRAF K601E affects the kinase activation segment of BRAF and has been associated with Raf/MEK/Erk pathway activation comparable to BRAF V600E. 10 It has also been described in cases of papillary thyroid cancer. Our data confirm the initial findings 3 that BRAF V600E is likely to be present in 100%
of patients with HCL with classic morphologic and immunophenotypic features. In addition, we observed that patients with morphologically classic HCL who have immunophenotypic variations (CD25-, CD10+, CD123-) also contain the BRAF V600E mutation.
From our data it appears that HRM and SS analysis are feasible strategies for the detection of the BRAF V600E mutation in unenriched bone marrow aspirate samples from patients with HCL, however, they also highlight potential challenges. Bone marrow fibrosis is common in patients with HCL which is probably secondary to cytokines produced by hairy cells themselves including FGF-2 14 and TGF-beta. 15 Fibrosis often results in suboptimal quality marrow aspirate samples containing only small numbers of hairy cells (despite extensive involvement on trephine biopsy). If HRM and SS are to be used on unenriched specimens in a diagnostic setting, it would be important to ensure adequate disease burden to avoid false-negative results. In the cases where the HRM is positive but SS is negative, it is possible to confirm the mutation by the low copy number approach. 16 An alternative technique in cases of low disease burden is allele-specific oligonucleotide PCR which has recently been shown to be a highly sensitive method for BRAF V600E detection in cases of hairy cell leukemia. [17] [18] In our cohort, bone marrow aspirates taken at initial diagnosis versus post-treatment had higher rates of BRAF V600E detection. This phenomenon presumably reflects higher estimated mutant allele percentages in these specimens but also provides evidence that BRAF V600E positive clones persist in relapsed disease without evidence of further mutations within the region sequenced.
In conclusion, our results confirm and extend the recent initial observations of Tiacci et al 3 and support the recent finding of a disease defining point mutation in HCL.
They also demonstrate that in the presence of adequate disease burden assessed morphologically, HRM and SS are feasible techniques to detect BRAF V600E in patients with HCL. We have also described the first case, to our knowledge, of an activating BRAF mutation in a patient with SMZL. The use of these simple, rapid
techniques that avoid complex sample processing will enhance their implementation in the diagnostic laboratory and aid in the diagnosis of HCL and related lymphoproliferative disorders.
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